Researchers funded by Cancer Research UK have made the biggest improvement in cervical cancer treatment in more than 20 years by changing how we use existing drugs.

Results from the INTERLACE trial show that giving cervical cancer patients a short course of chemotherapy before starting the standard treatment cuts the risk of death 40%. The new approach also cuts the risk of cervical cancer returning or relapsing (growing again after responding to treatment) by 35%.